Eric Shaff, Seres CEO
July 22, 2021 10:47 AM EDT
R&D

'By no means are we de­terred': Seres' stock spi­rals af­ter PhII mi­cro­bio­me fail in ul­cer­a­tive col­i­tis

Nicole DeFeudis

Editor

Al­most five years af­ter Seres Ther­a­peu­tics slammed in­to a Phase II fail­ure with its lead can­di­date, the mi­cro­bio­me pi­o­neer is re­port­ing an­oth­er mas­sive flop …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

A service from the Financial Times